SciSparc & Clearmind Patent for Depression Treatment
Ticker: SPRC · Form: 6-K · Filed: Mar 27, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, collaboration, pharmaceuticals, mental-health
TL;DR
SciSparc files new international patent for depression treatment with Clearmind, using SCI-110.
AI Summary
On March 27, 2024, SciSparc Ltd. announced a collaboration with Clearmind, resulting in a new international patent application. This application aims to prevent and treat depression using a novel combination of drugs, including SciSparc's proprietary drug SCI-110.
Why It Matters
This patent application could lead to new therapeutic options for depression, a widespread condition, potentially benefiting SciSparc's future product pipeline and market position.
Risk Assessment
Risk Level: medium — The success of the patent and the efficacy of the drug combination for treating depression are not yet proven, introducing clinical and regulatory risks.
Key Players & Entities
- SciSparc Ltd. (company) — Registrant
- Clearmind (company) — Collaborator
- SCI-110 (drug) — Proprietary drug used in patent application
- March 27, 2024 (date) — Date of press release
FAQ
What is the primary focus of the new international patent application filed by SciSparc and Clearmind?
The patent application is for preventing and treating depression using a novel combination of drugs, including SciSparc's SCI-110.
What is the significance of this patent application for SciSparc?
It represents an evolution of their collaboration with Clearmind and potentially expands their intellectual property in the area of mental health treatments.
When was this press release issued?
The press release was issued on March 27, 2024.
What is the name of SciSparc's proprietary drug mentioned in the filing?
The proprietary drug mentioned is SCI-110.
What type of filing is this document?
This document is a Form 6-K, a Report of Foreign Private Issuer.
Filing Stats: 315 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2024-03-27 09:18:33
Filing Documents
- ea0202675-6k_scisparc.htm (6-K) — 13KB
- ea020267501ex99-1_scisparc.htm (EX-99.1) — 7KB
- 0001213900-24-026259.txt ( ) — 21KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: March 27, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3